White Blood Cell Count — Immune System Biomarker

A white blood cell (WBC) count quantifies the concentration of leukocytes present in a specified volume of blood, typically reported as cells per microlitre or 10^9 cells per litre. White blood cells comprise several distinct functional subtypes, including neutrophils, lymphocytes, monocytes, eosinophils, and basophils. A comprehensive evaluation often pairs the total WBC count with a differential to assess the relative proportions of each cell type.

In healthy adults, normal reference ranges generally span between 4.0 and 11.0 × 10^9 cells per litre, though precise laboratory thresholds vary. In cancer care, fluctuations reflect both disease biology—such as bone marrow infiltration—and the suppressive impact of cytotoxic therapies on haematopoiesis.

Monitoring your white blood cell count protects you from dangerous infections. When treatments cause counts to drop severely—a condition termed leukopenia, or neutropenia when neutrophils are specifically low—even minor bacterial encounters can rapidly escalate into life-threatening infections. Tracking these numbers allows doctors to prescribe protective antibiotics, administer growth factors that boost bone marrow recovery, or briefly pause chemotherapy until your immune cells recover safely.

The white blood cell count is measured through a standard full blood count (FBC), also known as a complete blood count (CBC). This test is performed on a routine venous blood sample. Clinicians review both the total WBC and the absolute neutrophil count (ANC), which specifically highlights the primary defence cells against bacterial infections.

White blood cell counts are monitored across nearly all cancer types treated with chemotherapy, radiotherapy, or immunotherapy. They are particularly vital in haematological malignancies that arise directly within blood-forming tissues, such as acute and chronic leukaemias, myelodysplastic syndromes, and multiple myeloma, where malignant white cells can cause counts to become abnormally high or low.

If a patient's count is too low, scheduled chemotherapy cycles may be postponed or doses reduced to allow bone marrow recovery. Granulocyte colony-stimulating factors (G-CSF), such as filgrastim, may be injected to stimulate white cell production. If a patient develops a fever while counts are low (febrile neutropenia), emergency hospital admission and broad-spectrum antibiotics are immediately required.